Increased MAD2L2 expression predicts poor clinical outcome in Colon Adenocarcinoma
HAOTONG SUN1,2, HEYING WANG1,3, XIN LI1,2, YANJIE HAO1,2, JUN LING1,2, HUAN WANG1,2, FEIMIAO WANG1,2, FANG XU1,2,*
BIOCELL, Vol.47, No.3, pp. 607-618, 2023, DOI:10.32604/biocell.2023.026445
- 03 January 2023
(This article belongs to the Special Issue: Bioinformatics Study of Diseases)
Abstract Background: Colon adenocarcinoma (COAD) is the second leading cause of cancer death worldwide thus,
identification of COAD biomarkers is critical. Mitotic Arrest Deficient 2 Like 2 (MAD2L2) is a key factor in
mammalian DNA damage repair and is highly expressed in many malignant tumors. This is a comprehensive study
of MAD2L2 expression, its diagnostic value, prognostic analysis, potential biological function, and impact on the
immune system of patients with COAD. Methods: Gene expression, clinical relevance, prognostic analysis, diagnostic
value, GO/KEGG cluster analysis, data obtained from TCGA, and bioinformatics statistical analysis were performed
using the R package. Immune… More >